High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Additionally, AbbVie is an exceptional income stock. It's a Dividend King, with 52 consecutive years of payout increases including the time it spent under the wing of its former parent company, Abbott ...

AbbVie (NYSE: ABBV) and Amgen (NASDAQ ... the only medicine approved by the U.S. Food and Drug Administration for thyroid eye disease. The biotech giant could milk Tepezza in ways the smaller ...

AbbVie will pay Danish antibody specialist Genmab ... for Tepezza (teprotumumab), an antibody for the treatment of thyroid eye disease. Its biggest success to date by a long margin is the alliance ...

Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone ... The creation of AbbVie In 2011, Abbott announced it was to separate into two leading ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED ... more scrutiny into two of its largest businesses. AbbVie's experimental drug to treat early Parkinson's ...

AbbVie Inc. discovers, develops ... Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations ...